Behcet's Disease – Pipeline Review, H2 2011

Behcet's Disease – Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Behcet's Disease - Pipeline Review, H2 2011', provides an overview of the Behcet's Disease therapeutic pipeline. This report provides information on the therapeutic development for Behcet's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Behcet's Disease. 'Behcet's Disease - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Behcet's Disease.
• A review of the Behcet's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Behcet's Disease pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Behcet's Disease.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Behcet's Disease pipeline depth and focus of Behcet's Disease therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Behcet's Disease Overview
Therapeutics Development
An Overview of Pipeline Products for Behcet's Disease
Behcet's Disease Therapeutics under Development by Companies
Behcet's Disease Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Behcet's Disease Therapeutics – Products under Development by Companies
Behcet's Disease Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Behcet's Disease Therapeutics Development
Abbott Laboratories
Celgene Corporation
Amarillo Biosciences, Inc.
XOMA Ltd.
Behcet's Disease – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CC-10004 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Humira - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Interferon Alpha - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
XOMA 052 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Autologous Stem Cell Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
XOMA 052 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Adalimumab - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Rituximab - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Hematopoietic Stem Cell Transplantation + Cyclophosphamide + Anti-thymocyte Globulin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Recombinant Human Interferon-Alpha2a - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Behcet's Disease Therapeutics – Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Behcet's Disease, H2 2011
Products under Development for Behcet's Disease – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Abbott Laboratories, H2 2011
Celgene Corporation, H2 2011
Amarillo Biosciences, Inc., H2 2011
XOMA Ltd., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Behcet's Disease Therapeutics – Drug Profile Updates

LIST OF FIGURES

Number of Products under Development for Behcet's Disease, H2 2011
Products under Development for Behcet's Disease – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011 Skip to top